Genome & Company (KOSDAQ:314130)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,800.00
+70.00 (1.88%)
At close: Jul 27, 2026

Genome & Company Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
24,01624,58727,74514,29614,085451.25
Revenue Growth
-19.51%-11.38%94.07%1.50%3021.27%199.67%
Gross Profit
12,86413,40615,6704,0645,598374.24
Operating Income
-28,625-29,234-24,199-55,092-57,512-36,087
Net Income
-5,712-6,428-20,112-47,466-51,838-34,117
Earnings Per Share
-177.15-205.30-660.00-1680.81-1841.50-1269.10
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
60,77136,83080,93086,272106,69977,164
Total Debt
27,17018,96732,02426,4536,2916,826
Net Cash (Debt)
33,60117,86248,90659,819100,40870,338
Net Cash Growth
-26.13%-63.48%-18.24%-40.42%42.75%-34.77%
Net Cash Per Share
1042.13570.491604.882118.263566.882616.46

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-19,270-18,387-16,331-32,224-43,550-26,159
Capital Expenditures
-377.47-284.66-3,970-18,853-6,849-2,875
Free Cash Flow
-19,648-18,671-20,301-51,077-50,399-29,034
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
53.57%54.53%56.48%28.43%39.74%82.94%
Operating Margin
-119.19%-118.90%-87.22%-385.37%-408.34%-7997.20%
Pretax Margin
-36.48%-35.25%-101.69%-362.72%-412.03%-7978.71%
Profit Margin
-23.78%-26.14%-72.49%-332.02%-368.05%-7560.62%
FCF Margin
-81.81%-75.94%-73.17%-357.28%-357.83%-6434.20%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
6.729.703.0712.3317.461038.96